Company profile
Zentalis Pharmaceuticals, Inc.
NASDAQ: ZNTL · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
40DFH 44DQ 29GM —SS 55
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$137.1M
Employees
106
as of 2026-08-12
Market cap
$292.6M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$137.1M-$137.1M2025
Operating income-$152.8M-$152.8M2025
Total assets$289.0M$289.0M2025
Liabilities$72.8M$72.8M2025
Equity$216.2M$216.2M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Reportable100%
By geography
Not disclosed.
The read
What is Zentalis Pharmaceuticals, Inc.’s revenue?
Zentalis Pharmaceuticals, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Palisade Bio, Inc.71BSAB Biotherapeutics, Inc.52DInhibikase Therapeutics, Inc.43DEledon Pharmaceuticals, Inc.39DFulcrum Therapeutics, Inc.58CALX Oncology Holdings Inc.37DNeighbors
San Diego →Key facts
CEOJulia Marie Eastland
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: ZNTL
Employees106
IPO date2020-04-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.